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ABSTRACT
Prognosticating idiopathic pulmonary ibrosis (IPF) is 
challenging, in part due to a lack of sensitive biomarkers. 
A recent article in Thorax described how hyperpolarised 
xenon magnetic resonance spectroscopy may quantify 
regional gas exchange in IPF lungs. In a population of 
patients with IPF, we ind that the xenon signal from red 
blood cells diminishes relative to the tissue/plasma signal 
over a 12-month time period, even when the diffusion 
factor for carbon monoxide is static over the same time 
period. We conclude that hyperpolarised 129Xe MR 
spectroscopy may be sensitive to short-term changes in 
interstitial gas diffusion in IPF.
INTRODUCTION
Despite significant developments in our under-
standing of the pathogenesis of idiopathic pulmo-
nary fibrosis (IPF) and the emergence of efficacious 
treatments,1 2 prognostication remains challenging. 
Pulmonary function tests (PFTs), including forced 
vital capacity (FVC) and diffusing capacity of the 
lungs for carbon monoxide (D
LCO
), form the basis 
of assessing progression and treatment response, 
but are insensitive to longitudinal change.3 An FVC 
GHFOLQHRILVDYDOLGDWHGSULPDU\HQGSRLQWIRU
disease progression and is predictive of mortality,4 
but longitudinal data demonstrate substantial intra-
patient variability.3 New biomarkers may help to 
assess disease progression. MRI with hyperpolar-
ised helium (3He) or xenon (129Xe) gas can reveal 
subtle changes in lung ventilation and microstruc-
ture.5 Of particular interest for pulmonary gas 
exchange assessment is the solubility of xenon in 
lung parenchyma and blood.6 7 129Xe shows distinct 
signals from the red blood cells (RBCs) and intersti-
tial tissue/plasma (TP) compartments by virtue of its 
environment-dependent resonant frequency, which 
enables evaluation of gas exchange efficiency by 
MR spectroscopy (MRS). Wang et al recently used 
129Xe MRS to identify regions of gas transfer deficit 
in IPF.8 Herein, we describe preliminary findings 
evaluating the sensitivity of 129Xe MRS to longitu-
dinal physiological changes in patients with IPF.
METHODS
In a study with National Health Service Research 
Ethics Committee approval, 18 participants with 
a multidisciplinary diagnosis of IPF were recruited 
and provided prospective informed written 
consent. Five patients were taking antifibrotic treat-
ment on recruitment to the study (four on pirfeni-
done and one on nintedanib). During the study, a 
further three patients commenced pirfenidone and 
two patients commenced nintedanib. All underwent 
EDVHOLQHLPDJLQJDQGXQGHUZHQWUHSHDWHGVFDQV
13 hours later. Fourteen participants returned 
at 6 months (195±24 days) and 13 returned at 
12 months (361±31 days). Each underwent pulmo-
nary MRS with hyperpolarised 129Xe gas on a 1.5T 
whole-body MRI scanner. Scans were well tolerated 
and completed in all, except one participant at the 
12-month visit, who completed neither D
LCO
, nor 
the MR breath-hold manoeuvre.
129Xe was polarised under regulatory licence 
DQG P/ RI LVRWRSLFDOO\ HQULFKHG [HQRQ ZDV
balanced with nitrogen to a total inhaled dose of 
1 L. Whole lung 129Xe MRS was performed during 
D²VEUHDWKKROGDIWHULQKDOLQJWKHJDVPL[WXUH
from functional residual capacity. A pulse-acquire 
sequence was used to acquire whole-lung spectra 
of 129Xe in the TP and RBC compartments (band-
ZLGWKN+]IOLSDQJOHUHSHWLWLRQWLPHV
Data analysis was performed using MATLAB. After 
discarding the first spectrum, spectra were averaged 
and zeroth-order phased, and integrals over the 
RBC and TP spectral peaks were evaluated to derive 
the ratio RBC:TP.
PFTs were performed on the same day as MR. 
Spearmans r determined the strength of correla-
tions. Friedman tests evaluated the significance of 
differences in baseline, 6 and 12-month metrics. 
Intraclass correlation coefficient and Bland-Altman 
analyses assessed reproducibility of RBC:TP. 
7ZRWDLOHGSYDOXHVRIGHWHUPLQHGVWDWLVWLFDO
significance.
RESULTS
Summary statistics of demographics, PFTs and 
RBC:TP measurements (median (IQR)) are as 
follows: age (years) 71.5 (67.874.3); FVC 
SUHGLFWHG²'
LCO
SUHGLFWHG
 ² EDVHOLQH 5%&73  ²
 6DPHGD\ UHSHDW VFDQQLQJ \LHOGHG KLJKO\
reproducible intraparticipant RBC:TP ratios, (see 
Bland-Altman plot, figure 1; intraclass correlation 
 $ VWDWLVWLFDOO\ VLJQLILFDQW FRUUHODWLRQ U
&, ZDV REVHUYHG EHWZHHQ EDVHOLQH 5%&73
and D
LCO
 U   WR  EXW QRW
)9& U  ï WR  &RUUHODWLRQV
with D
LCO
 SUHGLFWHG UHPDLQHG VLJQLILFDQW DW
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PRQWKVU WRDQGPRQWKVU 
WR6WDWLVWLFDOO\VLJQLILFDQWFKDQJHVPHGLDQFKDQJH
&,)ULHGPDQSYDOXHZHUHVHHQRYHUPRQWKVLQ)9&
ï ï WR ï S  DQG 5%&73 ï
ï WRïS EXWQRW'
LCO
 ïïWR
 S  VHH figure 2. Although the mean observed 
decline in FVC was small, five patients demonstrated a relative 
)9&GHFOLQHGHILQHGDVFOLQLFDOO\VLJQLILFDQW4
DISCUSSION
Hyperpolarised 129Xe MRS is highly reproducible and sensitive 
to longitudinal changes in pulmonary gas exchange efficiency in 
IPF. The correlation between RBC:TP and D
LCO
 suggests the tech-
niques reflect similar underlying gas exchange pathophysiology, 
although with gases that have different membrane diffusion 
properties. While D
LCO
 showed no longitudinal change, RBC:TP 
demonstrated a trend to decline over 6 months and a statisti-
cally significant decline over 12 months. Our baseline RBC:TP 
and D
LCO
 correlation is slightly weaker than reported in8 possibly 
due to differences in MRS parameters, reference equations 
for D
LCO
, or inclusion of healthy volunteer data in previous 
correlations.8
D
LCO
 is calculated from exhaled gas concentrations measured 
at the mouth, while MRS obtains 129Xe measurements directly 
from the alveoli, alveolar-capillary membrane and RBCs. The 
observed reduction in RBC:TP when D
LCO
 is stable may there-
fore result from differing gas properties and measurement 
procedure, reflecting different pathophysiology. These differ-
ences may be emphasised by the postures used when measuring 
D
LCO
 (sitting) and 129Xe RBC:TP (supine). The supine posture 
may cause a partial redistribution of ventilation and perfusion 
to regions of the lung less affected by disease. Indeed, Wang et 
al demonstrated how TP signal increases and RBC signal falls 
in lung tissue afflicted with IPF and how RBC signal is almost 
absent in areas severely afflicted.8 The 129Xe signal from the 
tissue and RBC compartments is weighted by a combination 
of specific ventilation, interstitial thickening, delayed gas diffu-
sion and perfusion deficit. In future 129Xe spectroscopic studies, 
additional measurement the 129Xe alveolar gas signal as a refer-
ence, alongside contrast enhanced perfusion MRI may provide 
complementary physiological information to help understand 
the observed RBC:TP decline. Additionally, acquisition of 
longitudinal CT data could yield insight into the mechanism of 
Figure 1 Bland-Altman plot of 129Xe RBC:TP at baseline. Bland-
Altman plot of intraparticipant, interscan RBC:TP ratio reproducibility in 
10 participants, with the y-axis representing percentage error. Dashed 
line represents bias, with dotted lines representing 95% CIs. RBC, red 
blood cell; TP, tissue/plasma. 
Figure 2 Longitudinal change in FVC, D
LCO
 and RBC:TP. (A–C): Box and whisker diagrams with associated Friedman’s test p values, representing 
6-month and 12-month follow-up change in FVC, D
LCO
 and 129-xenon MR-derived RBC:TP ratio. Note that a statistically signiicant difference was 
not demonstrated in D
LCO
 (B), whereas FVC (A) and RBC:TP (C) declined signiicantly over 12 months. Individual participants’ metrics of FVC, D
LCO
 and 
RBC:TP at baseline, 6 and 12 months are plotted in (D), (E) and (F), respectively. D
LCO
, diffusing capacity of the lungs for carbon monoxide; FVC, forced 
vital capacity; RBC:TP, red blood cell to tissue/plasma. 
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RBC:TP change. We also note that inflation level may influence 
RBC:TP ratio in a non-negligible manner.9 Thus, future studies 
should consider varying the inhaled xenon gas dose with lung 
capacity.
Despite relatively limited participant numbers, we were able 
to identify a statistically significant decline in RBC:TP, indicating 
the power of this approach. The observed FVC decline is small, 
but consistent with treatment intervention studies1 2 and suggests 
a clinically significant decline in lung function and parallel gas 
exchange impairment. The decline observed in MRS-derived 
RBC:TP is underpinned by different pathophysiological mecha-
nisms to that in FVC, and thus, RBC:TP may be additive to our 
current repertoire of physiological assessment tools. With further 
development, this technique may offer a sensitive endpoint for 
early-stage clinical trials.
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